ReviewWorld journal of gastroenterology2018
Dimensions of hepatocellular carcinoma phenotypic diversity.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Artificial intelligence driven exposome and multi omics integration for biomarker discovery in liver cancer: a literature review.Frontiers in immunology · 2026Review
- Reactivation of the PI3K/mTOR Signaling Pathway Confers Resistance to the FGFR4 Inhibitor FGF401.International journal of molecular sciences · 2025Article
- Current research of the Notch pathway in hepatocellular carcinoma.European journal of medical research · 2025Review
- WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities.Genes & diseases · 2024Review
- Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.International journal of molecular sciences · 2024Article
- Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.BMC medical genomics · 2022Article
- Distinct phenotypic spectra of hepatocellular carcinoma in liver-specific tumor suppressor-deficient hepatitis B virus transgenic mice.Virology · 2022Article
- Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis.Hepatology communications · 2022Article
- Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown.Scientific reports · 2022Article
- Article
- Genetic Landscape of Multistep Hepatocarcinogenesis.Cancers · 2022Review
- Article
- Article
- Interplay between Metabolism Reprogramming and Epithelial-to-Mesenchymal Transition in Cancer Stem Cells.Cancers · 2021Review
- Article
- Differentially Expressed Long Noncoding RNAs Involved in FUBP1 Promoting Hepatocellular Carcinoma Cells Proliferation.BioMed research international · 2021Article
- Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma.World journal of gastroenterology · 2020Article
- Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the 3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.